Reacción a "Anti-amyloid drugs for Alzheimer's disease have not been shown to have clinically significant effects, according to a Cochrane review"

This Cochrane paper, recopilates 17 RCT including different drugs, with demosntrated different capacity for amyloid removal.  A strong, positive correlation exists between amyloid-beta plaque removal and clinical efficacy in early Alzheimer’s disease, with greater plaque reduction leading to slower cognitive and functional decline. 

In anti-amyloid antibody treatments, reducing plaque to a negative Amyloid PET scan level is not strictly required to observe a clinical effect, but it is highly correlated with greater benefits. Studies show that treatments like lecanemab and donanemab show significant plaque removal and slowed cognitive decline (about 27–35%) even before reaching fully negative PET levels, though maximum benefit is seen when patients reach amyloid-negative status. It is also important the velocity of amyloid removal. Both Lecanemab (55 centiloids in 18m) and DOnanemab (88 cetiloids in 18m) are the best mAbs described in the market with otther mAbs such as Trintinemab (90 centiloids in 3m).